Beiersdorf H1 Group Sales Up 2.1%; Updates FY Guidance

Beiersdorf reported a mixed H1 2025, with profit after tax declining to EUR561 million and organic sales growth slowing significantly to 2.1% from 7.1% in H1 2024, despite nominal sales reaching EUR5.188 billion. This performance, attributed to a weaker global skincare market, prompted the company to lower its full-year 2025 organic sales growth guidance to approximately 3% from a previous 4-6%. However, Beiersdorf still anticipates its consolidated EBIT margin to slightly exceed the prior year's level, with management expecting a second-half acceleration driven by new product innovations.

Analysis

Beiersdorf's first-half 2025 results illustrate a significant deceleration in performance, primarily driven by a slowdown in the global skincare market. Organic sales growth fell sharply to 2.1% from 7.1% in the prior-year period, with nominal sales up a marginal 0.2% to EUR 5.188 billion. This top-line weakness translated into lower profitability, with profit after tax declining to EUR 561 million from EUR 590 million and the operating margin (EBIT ex-special factors) slightly contracting to 16.1%. Consequently, the company has revised its full-year 2025 organic sales growth guidance downward to approximately 3% from a previous range of 4%-6%. Despite the challenging environment and a notable drop in gross cash flow to EUR 622 million, Beiersdorf is increasing capital expenditure, signaling continued investment in future growth. Management's outlook hinges on a second-half recovery fueled by product innovation, specifically citing the launch of the NIVEA Epigenetics Serum. A key mitigating factor is the company's expectation that the full-year consolidated EBIT margin will finish slightly above the prior year's 13.9% level, suggesting a focus on operational efficiency amidst revenue headwinds.

Key Decisions for Investors

• Investors should adjust full-year models to reflect the lowered organic sales growth guidance of approximately 3%, which signals near-term revenue pressure.
• The investment case is now heavily weighted towards a second-half recovery; therefore, closely monitor early sales data and market reception for new product launches like the NIVEA Epigenetics Serum.
• While the top-line slowdown is a concern, the stable full-year EBIT margin guidance suggests resilient profitability, which may offer downside support for the valuation.
• Note the deteriorating cash flow profile, as the decline in gross cash flow combined with rising capital expenditure could impact financial flexibility if the anticipated H2 sales acceleration fails to materialize.